CP-4126: A Novel Gemcitabine Derivative Targeting Pancreatic Cancer and Beyond
Discover the groundbreaking potential of CP-4126, a lipid-conjugated gemcitabine derivative engineered to overcome cancer drug resistance and improve patient outcomes in hard-to-treat malignancies.
Get a Quote & SampleProduct Core Value
LVT derivative of Gemcitabine
As a trusted supplier in China, we offer CP-4126, a novel Lipid Vector Technology (LVT) derivative of the anti-cancer drug gemcitabine. Its unique molecular design allows it to be absorbed by cancer cells independent of hENT1 levels, a critical factor in overcoming gemcitabine resistance. This bypass mechanism holds significant promise for improving treatment efficacy in patients who do not respond well to conventional gemcitabine therapy, particularly in pancreatic cancer.
- Explore the improved efficacy in resistant cancers: Leverage this cutting-edge pharmaceutical intermediate to develop next-generation oncology treatments.
- Understand the hENT1 independent gemcitabine therapy mechanism: This product offers a solution for patients with impaired drug entry into tumor cells, a key aspect of novel cancer therapeutic CP-4126 development.
- Leverage LVT gemcitabine cancer drug innovation: As a key pharmaceutical intermediate, it supports advancements in drug delivery for improved patient outcomes.
- Support research into pancreatic cancer treatment CP-4126: Facilitate critical studies aiming to enhance the therapeutic landscape for this challenging disease.
Advantages Provided by the Product
Enhanced Therapeutic Efficacy
CP-4126 provides enhanced therapeutic efficacy by bypassing hENT1 transporter dependency, a crucial factor in overcoming gemcitabine resistance. This makes it a vital component for novel cancer therapeutic CP-4126 research.
Broadened Patient Applicability
Its ability to enter cancer cells regardless of hENT1 expression significantly broadens the patient population that can benefit from this innovative drug delivery approach, supporting LVT gemcitabine cancer drug advancements.
Overcoming Drug Resistance
This gemcitabine derivative is specifically designed to overcome common mechanisms of resistance, offering a new avenue for treating difficult cancers and advancing the field of pancreatic cancer treatment CP-4126.
Key Applications
Oncology Drug Development
As a critical pharmaceutical intermediate, CP-4126 is central to the development of advanced oncology drugs, supporting the creation of novel cancer therapeutic CP-4126 solutions.
Advanced Cancer Therapeutics
This LVT gemcitabine cancer drug derivative is essential for creating next-generation therapies, particularly for challenging cancers like pancreatic cancer treatment CP-4126.
Pharmaceutical Intermediate Innovation
Utilize this intermediate to drive innovation in drug delivery and formulations, enhancing the reach of hENT1 independent gemcitabine therapy.
Targeted Cancer Therapies
CP-4126 is a key component in developing targeted cancer therapies that overcome specific resistance mechanisms, furthering research into pancreatic cancer treatment CP-4126.